NP-delivered intervention fails to reduce early symptom burden during chemo
the ONA take:
A nurse practitioner (NP)-delivered symptom management intervention did not appear to reduce symptom burden compared with standard care among patients initiating chemotherapy for nonmetastatic cancer, a new study published in the journal Cancer has shown.
For the study, researchers sought to determine whether an NP-delivered symptom management intervention would reduce patient-reported symptom burden among patients initiating chemotherapy for nonmetastatic cancer.
Researchers enrolled 120 patients with nonmetastatic breast, colorectal, or lung cancer and randomly assigned them to receive standard care alone or standard care plus the intervention.
Patients assigned to the intervention group received telephone calls from their oncology NP during the week after each of the first two visits for chemotherapy administration.
Results showed that 50.8% of patients reported at least one physical symptom at the time of the first chemotherapy administration visit. Researchers found that the number of symptoms, symptom distress, and satisfaction with care increased, while the risk for anxiety symptoms decreased.
The likelihood of depression symptoms did not change over time. There was no difference in the reduction of patient-reported symptom burden between the two arms.
The findings suggest that it is important to continue identifying strategies to improve symptom management, particularly early symptoms, during chemotherapy for patients with nonmetastatic disease.
A nurse practitioner-delivered symptom management intervention did not appear to reduce symptom burden.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|